Genomics BioSci & Tech. Co.Ltd.
Genomics BioSci & Tech. Co.,Ltd. operates as a genomic company in Taiwan. The company offers sequencing, synthesis, genomic, proteomic, and agency and sales services; reproductive health and cancer testing services; and contract development and manufacturing services. Genomics BioSci & Tech. Co.,Ltd. was founded in 2001 and is based in New Taipei City, Taiwan.
Genomics BioSci & Tech. Co.Ltd. (4195) - Total Liabilities
Latest total liabilities as of June 2024: NT$479.36 Million TWD
Based on the latest financial reports, Genomics BioSci & Tech. Co.Ltd. (4195) has total liabilities worth NT$479.36 Million TWD as of June 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Genomics BioSci & Tech. Co.Ltd. - Total Liabilities Trend (2019–2023)
This chart illustrates how Genomics BioSci & Tech. Co.Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Genomics BioSci & Tech. Co.Ltd. Competitors by Total Liabilities
The table below lists competitors of Genomics BioSci & Tech. Co.Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Grupo Concesionario del Oeste SA
BA:OEST
|
Argentina | AR$124.49 Billion |
|
Halmont Properties Corporation
V:HMT
|
Canada | CA$142.65 Million |
|
C3 Metals Inc
OTCQB:CUAUF
|
USA | $1.11 Million |
|
EBQLF
PINK:EBQLF
|
USA | $46.12 Million |
|
Medical Developments International Limited
PINK:MDDVF
|
USA | $11.29 Million |
|
Atrium Real Estate Investment Trust
KLSE:5130
|
Malaysia | RM354.81 Million |
|
Ideal Bike
TWO:8933
|
Taiwan | NT$1.95 Billion |
Liability Composition Analysis (2019–2023)
This chart breaks down Genomics BioSci & Tech. Co.Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.09 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.69 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.37 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Genomics BioSci & Tech. Co.Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Genomics BioSci & Tech. Co.Ltd. (2019–2023)
The table below shows the annual total liabilities of Genomics BioSci & Tech. Co.Ltd. from 2019 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | NT$368.33 Million | +11.41% |
| 2022-12-31 | NT$330.60 Million | +90.17% |
| 2021-12-31 | NT$173.84 Million | -29.78% |
| 2020-12-31 | NT$247.56 Million | +11.18% |
| 2019-12-31 | NT$222.66 Million | -- |